Integrated Biopharma INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQX
Integrated BioPharma, Inc. reported an 8% increase in net sales and a significant rise in net income for the fiscal year ended June 30, 2025, driven by growth in both Contract Manufacturing and Other Business Lines segments.
OQX
Integrated BioPharma experienced a minor decrease in revenue but achieved net income in fiscal year 2024, according to its latest 10-K filing.